Phase Ib Trial of ABBV-637 or ABBV-155 in Combination With ERAS-801 for Glioblastoma With Amplification of the Epidermal Growth Factor Receptor
Latest Information Update: 21 Oct 2025
At a glance
- Drugs ABBV-637 (Primary) ; ERAS-801 (Primary) ; Mirzotamab clezutoclax (Primary) ; Temozolomide
- Indications Glioblastoma; Gliosarcoma
- Focus Adverse reactions
Most Recent Events
- 21 Oct 2025 New trial record